Expression of microRNA-106b and its clinical significance in cutaneous melanoma

Abstract

ABSTRACT. is overexpressed in various types of cancers and is associated with the regulation of carcinogenic processes. However, its clinical significance in cutaneous melanoma has not been reported. qRT-PCR was performed to examine the expression of miR-106b in 15 cases of dysplastic nevi, 17 cases of melanoma metastases, and 97 cases of primary cutaneous melanoma tissue samples. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis. Significant differences in miR-106b expression were shown between dysplastic nevi and primary cutaneous melanomas (P < 0.01), between primary melanomas and metastatic cutaneous melanomas (P < 0.01), and between primary cutaneous melanomas and metastatic cutaneous melanomas (P < 0.001). We found that high miR106b expression was correlated with Breslow thickness (P = 0.002), tumor ulceration (P = 0.002), and advanced clinical stage (P < 0.001). The patients with high miR-106b expression showed shorter 5-year overall survival than those with low miR-106b expression (P = 0.02; log-rank test). Multivariate regression analysis showed that the status of miR-106b expression was an independent prognostic factor for overall survival (HR = 2.09, 95%CI: 1.11-10.26, P = 0.02). This study showed that miR-106b may contribute 16379-16385 (2015) to the progression of cutaneous melanoma and its up-regulation may be independently associated with poor prognosis of cutaneous melanoma. This suggests that miR-106b might serve as a promising biological marker for further risk stratification in the management of cutaneous melanoma.

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

“…A large number of experimental studies have demonstrated that miR-126-3p, beside regulating angiogenesis and vessel integrity, acts as a tumor suppressor in a variety of tumors, including melanoma, through negative modulation of proliferation, migration and invasion [26, 42, 56]. Moreover, Lin et al [57] demonstrated a progressive decrease of miR-126-3p levels in dysplastic nevi, primary melanomas and melanoma metastases and a shorter 5-years overall survival in patients with primary tumor expressing low miR-126-3p levels. Down-regulation of miR-126-3p has also been implicated in acquired resistance of cervical cancer cells to TRAIL [58], and of gastric cancer cells to vincristine and adriamycin [59].…”

Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes

“…The main characteristics of included studies included in the present analysis was summarized in Table 1 and Table 2 . Of these 26 studies, 20 [ 15 , 17 , 21 – 30 , 32 – 37 , 39 , 41 ] studies were conducted among the Asian, and the rest [ 16 , 20 , 31 , 38 , 40 , 42 ] were among the Caucasian. Besides this, 21 [ 16 , 17 , 20 – 23 , 27 – 29 , 31 – 42 ] studies used tumor tissues to detect miRNAs concentrations, 4 [ 15 , 24 – 26 ] studies used blood samples, and 1 [ 30 ] study tested in both tissue and serum samples.…”

“…We extract data from these 26 studies, which included 3189 participants in total. The type of cancers assessed in these studies included colorectal cancer (CRC) [ 20 – 25 ], lung cancer [ 15 , 26 , 27 ], hepatocellular carcinoma (HCC) [ 17 , 28 , 29 ], breast cancer (BC) [ 16 , 30 ], esophageal squamous cell carcinoma (ESCC) [ 31 , 32 ], glioma [ 33 , 34 ], pancreatic cancer (PC) [ 35 , 36 ], BL (including T-cell lymphoblastic lymphoma [ 37 ], Burkitt lymphoma [ 38 ]) and others (astrocytoma [ 39 ], gastrointestinal cancer [ 40 ], melanoma [ 41 ], and ependymomas [ 42 ]). Quantitative real-time PCR (qRT-PCR) was used in 25 studies to assess miRNA expression, and only 1 study exploited microarray analysis.…”

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

“…87 Expression of various miRNAs at abnormal levels has been shown to correlate with disease stage and recurrence. 88,89 Finally, circulating tumor DNA (ctDNA) found in the plasma has been investigated as a means to determine disease status in patients with advanced melanoma. 90 This ctDNA can both provide insights into total tumor load and into tumor-associated mutations.…”